30 closest matches · ranked by relevance
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Primary: Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen — 0; 1; 0 Participants
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants
Ovarian Cancer
Primary: Part 2: Median Progression-free Survival (PFS) in Weeks Based on Enhanced Response Evaluation Criteria In Solid Tumors Version 1.1 (Enhanced RECIST 1.1) by Independent…
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression-free Survival — 8.85; 8.32 months
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Primary: Objective Response Rate (ORR) — 1; 11; 7; 8 Participants
Ovarian Cancer
Primary: Progression Free Survival (PFS) (According to Response Evaluation Criteria in Solid Tumours [RECIST]) — 8.4; 4.8 Months — p=<0.00001
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate (ORR) — 109; 37 Count of Participants — p=0.002
Germline BRCA1/2 Mutations and · Metastatic Adenocarcinoma of the Pancreas
Primary: Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified…
Ovarian Cancer
Primary: Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR) — 11.3; 13.0; 12.2; 6.9 Percentage of Participants
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate, Defined as the Percentage of Subjects With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) — 69.3; 64.0…
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Clinical Benefit Rate [CBR] — 12 Participants
Breast Cancer
Primary: Objective Response Rate — 3; 19; 4; 57 Participants
Non-Germline BRCA Mutated Ovarian Cancer
Primary: Progression Free Survival (PFS) — 9.2 months
Ovarian Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events — 2; 0 Participants
Anti-p53 TCR-Gene
Primary: Clinical Tumor Regression — 1 Participants
Ovarian Cancer · Primary Peritoneal Cancer
Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Primary: Number of Participants With Drug-related Adverse Events (AEs) of Grade 3 or Higher — 20 Participants
Recurrent Epithelial Ovarian Cancer · Recurrent Fallopian Tube Cancer · Recurrent Primary Peritoneal Cancer
Primary: Overall Response Rate (ORR) — 4 participants
Ovarian Cancer
Primary: Progression-free Survival (PFS) — 13.7; 8.4 months
Ovarian Cancer
Primary: Progression-free Survival by Independent Review Committee — 3.5; 3.6 months — p=0.6294
Recurrent Platinum Resistant Ovarian Cancer
Primary: Mean Objective Response Rate (ORR) by Independent Central Review (ICR) Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 15.3 percentage of…
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…
Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 10; 5; 2 Participants
Recurrent Platinum-resistant Ovarian Cancer
Primary: Phase 1: Number of Subjects With Treatment-Emergent Adverse Events (TEAE) of Grade Greater Than or Equal to (≥) 3 in Severity — 26; 12; 6; 1 Participants
Ovarian Cancer
Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…
Ovarian Neoplasms · Platinum Sensitive Ovarian Cancer
Primary: Progression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA) — 21; 5.5 months — p=<0.0001
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Maximum Tolerated Dose (MTD) — 105 mg/m^2
Ovarian Cancer
Primary: PFS — 29.8 Months
Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma
Primary: Objective Response Rate (ORR) — 2; 0 Participants
Ovarian Cancer
Primary: Part 1: Percentage of Participants With Adverse Events (AEs) — 95.5; 100.0 percentage of participants